New Precision Strategies for HER2+ GEA: Interpreting New Data to Inform Clinical Practice

Activity Overview

HER2-positive gastroesophageal adenocarcinomas (GEAs) have traditionally been associated with limited treatment options and poor prognosis. In the setting of metastatic disease, the introduction of HER2-directed therapy and immunotherapy has led to a dramatic improvement in outcomes for patients. However, appropriate use of these agents requires careful assessment of potentially actionable molecular targets along the treatment continuum, and this necessitates coordination with the molecular pathology team to ensure appropriate tissue stewardship and interpretation of test reports.

In this second of 2 podcasts focused on HER2-positive advanced or metastatic GEAs, Rahul Gosain, MD; and Rohit Gosain, MD, discuss the emerging use of novel anti-HER2 therapies, with an emphasis on supporting data and effective management of adverse events.

Target Audience

This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses who are involved in the management of patients with advanced or metastatic gastroesophageal adenocarcinomas (GEA).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate emerging clinical trial data assessing novel HER2-targeted treatment strategies for GEA
• Implement strategies to mitigate and manage AEs associated with HER2-targeted therapy